Kirk Tanner

Company: National Brain Tumor Society

Job title: Chief Scientific Officer

Seminars:

DDRi R&D in CNS Tumors: Landscape & Opportunities 3:30 pm

 Understanding the strong rationale for DDRi’s in CNS Tumors Optimizing systematic and efficient experimental drug qualification as a key opportunity to make profound impact on devastating diseases with a strong commercial caseRead more

day: Day Two

Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian 9:30 am

Sharing insights into future directions and what to anticipate as standards evolve for PARP and other DDRi’s in the clinic How is it looking for prostate? leukemia? GBM? pancreatic? endometrial? SCLC? What are the differences between cancers in terms of resistance to PARP inhibitors? Thoughts on moving to a more genomic rather than indication-specific biomarker-driven…Read more

day: Day One